DMXE

deoxymethoxetamine

Sources

2 strong · 10 moderate · 13 weak

Studies and references cited across this article, graded by evidence strength.

Values approved

236/236 (100%)

Data points an editor reviewed and accepted for publication.

Value Provenance

Dosing

insufflatedtrace

Field	Published	AI Proposed	Confidence
Threshold	5 mg	5 mg	low
Low	5–20 mg	5–20 mg	low
Common	20–35 mg	20–35 mg	low
Strong	35–60 mg	35–60 mg	low
Heavy	60+ mg	60+ mg	low
Editorial	Community consensus from PsychonautWiki, Bluelight Big & Dandy DMXE thread, and Grokipedia. No controlled dose-finding studies exist. Threshold ~5 mg, light 5-20 mg, common 20-35 mg, strong 35-60 mg, heavy 60+ mg. Trip reports consistent across sources (20 mg described as barely discernible, 50 mg as rushing euphoria, 70 mg in multiple reports). Safety margin unknown — no LD₅₀ data.
	ReasoningReasoning Community consensus from PsychonautWiki, Bluelight Big & Dandy DMXE thread, and Grokipedia. No controlled dose-finding studies exist. Threshold ~5 mg, light 5-20 mg, common 20-35 mg, strong 35-60 mg, heavy 60+ mg. Trip reports consistent across sources (20 mg described as barely discernible, 50 mg as rushing euphoria, 70 mg in multiple reports). Safety margin unknown — no LD₅₀ data. Evidence basis: community_consensus_small

oraltrace

Field	Published	AI Proposed	Confidence
Threshold	10 mg	10 mg	low
Low	10–35 mg	10–35 mg	low
Common	35–55 mg	35–55 mg	low
Strong	55–90 mg	55–90 mg	low
Heavy	90+ mg	90+ mg	low
Editorial	Estimated from insufflated doses using 1.5-2x multiplier per community inference (Bluelight, Grokipedia). No precise oral dose consensus exists. Work-notes specify threshold ~8-10 mg, light ~10-35 mg, common ~35-55 mg, strong ~55-90 mg, heavy ~90+ mg. These are structural analog inferences with widened ranges. All values require editorial review — oral bioavailability unknown.
	ReasoningReasoning Estimated from insufflated doses using 1.5-2x multiplier per community inference (Bluelight, Grokipedia). No precise oral dose consensus exists. Work-notes specify threshold ~8-10 mg, light ~10-35 mg, common ~35-55 mg, strong ~55-90 mg, heavy ~90+ mg. These are structural analog inferences with widened ranges. All values require editorial review — oral bioavailability unknown. Evidence basis: structural_analogy

Duration

insufflated

Field	Published	AI Proposed	Confidence
Peaktrace	1–3 hours	1–3 hours	low
Editorial	Community consensus (PsychonautWiki, Bluelight, Grokipedia). Work-notes specify 1-3 hours peak for insufflated.
	ReasoningReasoning Community consensus (PsychonautWiki, Bluelight, Grokipedia). Work-notes specify 1-3 hours peak for insufflated. Evidence basis: community_consensus_small
Onsettrace	5–15 minutes	5–15 minutes	low
Editorial	Community consensus from PsychonautWiki and Grokipedia. Consistent with arylcyclohexylamine intranasal pharmacokinetics.
	ReasoningReasoning Community consensus from PsychonautWiki and Grokipedia. Consistent with arylcyclohexylamine intranasal pharmacokinetics. Evidence basis: community_consensus_small
Come uptrace	15–30 minutes	15–30 minutes	low
Editorial	Community reports (PsychonautWiki, Grokipedia). Work-notes specify 15-30 min come_up for insufflated.
	ReasoningReasoning Community reports (PsychonautWiki, Grokipedia). Work-notes specify 15-30 min come_up for insufflated. Evidence basis: community_consensus_small
Offsettrace	1–2 hours	1–2 hours	low
Editorial	Community reports. Work-notes specify 1-2 hours offset for insufflated.
	ReasoningReasoning Community reports. Work-notes specify 1-2 hours offset for insufflated. Evidence basis: community_consensus_small
Totaltrace	2–6 hours	2–6 hours	low
Editorial	Community consensus from PsychonautWiki and Grokipedia. Work-notes specify 2-6 hours total for insufflated. This represents subjective experience duration, not pharmacological elimination.
	ReasoningReasoning Community consensus from PsychonautWiki and Grokipedia. Work-notes specify 2-6 hours total for insufflated. This represents subjective experience duration, not pharmacological elimination. Evidence basis: community_consensus_small
After effectstrace	2–12 hours	2–12 hours	low
Editorial	Work-notes specify 2-12 hours aftereffects, inferred from NMDA antagonist class. Wide range reflects individual variability and absence of pharmacokinetic data.
	ReasoningReasoning Work-notes specify 2-12 hours aftereffects, inferred from NMDA antagonist class. Wide range reflects individual variability and absence of pharmacokinetic data. Evidence basis: structural_analogy

oral

Field	Published	AI Proposed	Confidence
Onsettrace	15–30 minutes	15–30 minutes	low
Editorial	Limited community reports (Bluelight, Grokipedia). Work-notes specify 15-30 min onset for oral.
	ReasoningReasoning Limited community reports (Bluelight, Grokipedia). Work-notes specify 15-30 min onset for oral. Evidence basis: community_consensus_small
Come uptrace	30–60 minutes	30–60 minutes	low
Editorial	Community reports. Work-notes specify 30-60 min come_up for oral. Slower absorption than insufflated.
	ReasoningReasoning Community reports. Work-notes specify 30-60 min come_up for oral. Slower absorption than insufflated. Evidence basis: community_consensus_small
Peaktrace	1.5–3.5 hours	1.5–3.5 hours	low
Editorial	Limited community reports. Work-notes specify 1.5-3.5 hours peak for oral. Longer and more rounded than insufflated.
	ReasoningReasoning Limited community reports. Work-notes specify 1.5-3.5 hours peak for oral. Longer and more rounded than insufflated. Evidence basis: community_consensus_small
Offsettrace	1–3 hours	1–3 hours	low
Editorial	Community reports. Work-notes specify 1-3 hours offset for oral.
	ReasoningReasoning Community reports. Work-notes specify 1-3 hours offset for oral. Evidence basis: community_consensus_small
Totaltrace	3–7 hours	3–7 hours	low
Editorial	Community consensus. Work-notes specify 3-7 hours total for oral. Represents subjective experience only.
	ReasoningReasoning Community consensus. Work-notes specify 3-7 hours total for oral. Represents subjective experience only. Evidence basis: community_consensus_small
After effectstrace	2–12 hours	2–12 hours	low
Editorial	Work-notes specify 2-12 hours aftereffects for oral, inferred from NMDA antagonist class. Same wide range as insufflated due to absent PK data.
	ReasoningReasoning Work-notes specify 2-12 hours aftereffects for oral, inferred from NMDA antagonist class. Same wide range as insufflated due to absent PK data. Evidence basis: structural_analogy

Safety

Toxicity Profiletrace

Field	Published	AI Proposed	Confidence
Acute	moderate	moderate	low
Chronic	moderate	moderate	low
Organs Affected	cardiovascular, renal, neurological, urological	cardiovascular, renal, neurological, urological	low
Editorial	Work-notes specify moderate acute and moderate chronic toxicity, both class-extrapolated. Zero published DMXE toxicology cases (CFSRE Oct 2025). 'Moderate' acute reflects potent NMDA antagonism + class seizure/cardiovascular risk from MXE; 'moderate' chronic reflects ketamine-class uropathy. Evidence discount applied: all data is structural analog inference, confidence set to low.
	ReasoningReasoning Work-notes specify moderate acute and moderate chronic toxicity, both class-extrapolated. Zero published DMXE toxicology cases (CFSRE Oct 2025). 'Moderate' acute reflects potent NMDA antagonism + class seizure/cardiovascular risk from MXE; 'moderate' chronic reflects ketamine-class uropathy. Evidence discount applied: all data is structural analog inference, confidence set to low. Evidence basis: structural_analogy

Dependence Profiletrace

Field	Published	AI Proposed	Confidence
Physical	negligible	negligible	low
Psychological	moderate	moderate	low
Compulsive Redosing	high	high	low
Dose Escalation	moderate	moderate	low
Editorial	Work-notes specify negligible physical, moderate psychological dependence, moderate-high compulsive redosing (mapped to 'high'), and moderate dose escalation. All from community reports (Bluelight, Erowid) and MXE class inference (Zanda 2016). No formal dependence liability assessment exists for DMXE.
	ReasoningReasoning Work-notes specify negligible physical, moderate psychological dependence, moderate-high compulsive redosing (mapped to 'high'), and moderate dose escalation. All from community reports (Bluelight, Erowid) and MXE class inference (Zanda 2016). No formal dependence liability assessment exists for DMXE. Evidence basis: community_consensus_small

Withdrawal Profiletrace

Field	Published	AI Proposed	Confidence
Severity	mild	mild	low
Symptoms	anhedonia, cognitive dullness, cravings, low motivation	anhedonia, cognitive dullness, cravings, low motivation	low
Fatal	No	No	low
Medical Supervision	Not required	Not required	low
Editorial	No characterized physical withdrawal syndrome for DMXE. NMDA antagonist class does not typically produce opioid- or benzodiazepine-like withdrawal. Psychological symptoms (anhedonia, cognitive dullness, cravings) may occur after cessation of heavy use, per work-notes and community reports.
	ReasoningReasoning No characterized physical withdrawal syndrome for DMXE. NMDA antagonist class does not typically produce opioid- or benzodiazepine-like withdrawal. Psychological symptoms (anhedonia, cognitive dullness, cravings) may occur after cessation of heavy use, per work-notes and community reports. Evidence basis: community_consensus_small

Tolerance Profiletrace

Field	Published	AI Proposed	Confidence
Buildup	rapid	rapid	low
Half-life	3 days	3 days	low
Full Reset	14 days	14 days	low
Cross-tolerances	ketamine, methoxetamine, phencyclidine, deschloroketamine, 2-FDCK, O-PCE	ketamine, methoxetamine, phencyclidine, deschloroketamine, 2-FDCK, O-PCE	low
Editorial	Work-notes specify rapid buildup, no half-life data (proposed with low confidence), full reset 1-2 weeks from NMDA class inference. Cross-tolerances with all listed NMDA antagonists by shared mechanism. Community reports confirm rapid within-session and across-session tolerance (Bluelight, Erowid).
	ReasoningReasoning Work-notes specify rapid buildup, no half-life data (proposed with low confidence), full reset 1-2 weeks from NMDA class inference. Cross-tolerances with all listed NMDA antagonists by shared mechanism. Community reports confirm rapid within-session and across-session tolerance (Bluelight, Erowid). Evidence basis: structural_analogy

Effects & Profile

Contraindications

Field	Published	AI Proposed	Confidence
psychiatric Psychotic disorders (personal or family history)trace	absolute	absolute	medium
Editorial	Class-level evidence from MXE and 3-MeO-PCP case reports documenting substance-induced psychosis in arylcyclohexylamine users. No DMXE-specific psychosis cases, but mechanism is identical.
	ReasoningReasoning Class-level evidence from MXE and 3-MeO-PCP case reports documenting substance-induced psychosis in arylcyclohexylamine users. No DMXE-specific psychosis cases, but mechanism is identical.
other Concurrent MAO inhibitor usetrace	absolute	absolute	low
Editorial	Structural analog inference from MXE's SERT affinity (Roth et al. 2013) plus class-level MAOI interaction risk. Severity uncharacterized but mechanistically dangerous. Community consensus supports avoidance.
	ReasoningReasoning Structural analog inference from MXE's SERT affinity (Roth et al. 2013) plus class-level MAOI interaction risk. Severity uncharacterized but mechanistically dangerous. Community consensus supports avoidance.
other Concurrent high-dose SNRI/SSRI usetrace	absolute	absolute	low
Editorial	Structural analog inference: MXE has confirmed SERT affinity; O-PCE + venlafaxine fatality (Theofel et al. 2019) is the most relevant safety case for this drug class. DMXE SERT activity uncharacterized.
	ReasoningReasoning Structural analog inference: MXE has confirmed SERT affinity; O-PCE + venlafaxine fatality (Theofel et al. 2019) is the most relevant safety case for this drug class. DMXE SERT activity uncharacterized.
cardiovascular Cardiovascular diseasetrace	relative	relative	medium
Editorial	Class-level evidence from MXE case reports documenting tachycardia, bradycardia, ST-segment changes. No DMXE-specific cardiovascular data.
	ReasoningReasoning Class-level evidence from MXE case reports documenting tachycardia, bradycardia, ST-segment changes. No DMXE-specific cardiovascular data.
renal Renal impairmenttrace	relative	relative	low
Editorial	Structural analog inference from 3-methyl-PCP rhabdomyolysis/AKI case (Deutsch et al. 2026). DMXE shares the 3-methylphenyl ring. No direct DMXE renal data.
	ReasoningReasoning Structural analog inference from 3-methyl-PCP rhabdomyolysis/AKI case (Deutsch et al. 2026). DMXE shares the 3-methylphenyl ring. No direct DMXE renal data.
hepatic Hepatic impairmenttrace	relative	relative	low
Editorial	Class inference from MXE CYP2B6/CYP3A4 metabolism (Meyer et al. 2013). No DMXE-specific hepatic data. Pharmacokinetic prediction only.
	ReasoningReasoning Class inference from MXE CYP2B6/CYP3A4 metabolism (Meyer et al. 2013). No DMXE-specific hepatic data. Pharmacokinetic prediction only.
neurological History of seizure disordertrace	relative	relative	medium
Editorial	Class-level evidence from MXE seizure case (Imbert et al. 2014). NMDA antagonist mechanism of cortical disinhibition supports seizure risk. No DMXE-specific seizure reports.
	ReasoningReasoning Class-level evidence from MXE seizure case (Imbert et al. 2014). NMDA antagonist mechanism of cortical disinhibition supports seizure risk. No DMXE-specific seizure reports.
pregnancy breastfeeding Pregnancytrace	absolute	absolute	low
Editorial	Mechanistic inference from NMDA receptor role in neurodevelopment. No DMXE reproductive toxicity data. Standard precautionary contraindication for NMDA antagonists.
	ReasoningReasoning Mechanistic inference from NMDA receptor role in neurodevelopment. No DMXE reproductive toxicity data. Standard precautionary contraindication for NMDA antagonists.
other Lower urinary tract diseasetrace	relative	relative	medium
Editorial	Class-level evidence from ketamine uropathy literature (Castellani et al. 2020, BAUS consensus 2024). No DMXE-specific urological data. Chronic use concern.
	ReasoningReasoning Class-level evidence from ketamine uropathy literature (Castellani et al. 2020, BAUS consensus 2024). No DMXE-specific urological data. Chronic use concern.

Timeline Phases

insufflated

Field	Published	AI Proposed	Confidence
Come uptrace	900–1800 sec(i=0.40)	900–1800 sec(i=0.40)	low
Editorial	All timeline data from community consensus (PsychonautWiki, Grokipedia, Bluelight). No controlled pharmacokinetic studies. Work-notes specify onset 5-15 min, come_up 15-30 min, peak 1-3 hours, offset 1-2 hours, afterglow 2-12 hours for insufflated ROA. Driving advisory verbatim from work-notes.
	ReasoningReasoning All timeline data from community consensus (PsychonautWiki, Grokipedia, Bluelight). No controlled pharmacokinetic studies. Work-notes specify onset 5-15 min, come_up 15-30 min, peak 1-3 hours, offset 1-2 hours, afterglow 2-12 hours for insufflated ROA. Driving advisory verbatim from work-notes. Evidence basis: community_consensus_small
Onsettrace	300–900 sec(i=0.10)	300–900 sec(i=0.10)	low
Editorial	All timeline data from community consensus (PsychonautWiki, Grokipedia, Bluelight). No controlled pharmacokinetic studies. Work-notes specify onset 5-15 min, come_up 15-30 min, peak 1-3 hours, offset 1-2 hours, afterglow 2-12 hours for insufflated ROA. Driving advisory verbatim from work-notes.
	ReasoningReasoning All timeline data from community consensus (PsychonautWiki, Grokipedia, Bluelight). No controlled pharmacokinetic studies. Work-notes specify onset 5-15 min, come_up 15-30 min, peak 1-3 hours, offset 1-2 hours, afterglow 2-12 hours for insufflated ROA. Driving advisory verbatim from work-notes. Evidence basis: community_consensus_small
Peaktrace	3600–10800 sec(i=1.00)	3600–10800 sec(i=1.00)	low
Editorial	All timeline data from community consensus (PsychonautWiki, Grokipedia, Bluelight). No controlled pharmacokinetic studies. Work-notes specify onset 5-15 min, come_up 15-30 min, peak 1-3 hours, offset 1-2 hours, afterglow 2-12 hours for insufflated ROA. Driving advisory verbatim from work-notes.
	ReasoningReasoning All timeline data from community consensus (PsychonautWiki, Grokipedia, Bluelight). No controlled pharmacokinetic studies. Work-notes specify onset 5-15 min, come_up 15-30 min, peak 1-3 hours, offset 1-2 hours, afterglow 2-12 hours for insufflated ROA. Driving advisory verbatim from work-notes. Evidence basis: community_consensus_small
Resolutiontrace	3600–7200 sec(i=0.40)	3600–7200 sec(i=0.40)	low
Editorial	All timeline data from community consensus (PsychonautWiki, Grokipedia, Bluelight). No controlled pharmacokinetic studies. Work-notes specify onset 5-15 min, come_up 15-30 min, peak 1-3 hours, offset 1-2 hours, afterglow 2-12 hours for insufflated ROA. Driving advisory verbatim from work-notes.
	ReasoningReasoning All timeline data from community consensus (PsychonautWiki, Grokipedia, Bluelight). No controlled pharmacokinetic studies. Work-notes specify onset 5-15 min, come_up 15-30 min, peak 1-3 hours, offset 1-2 hours, afterglow 2-12 hours for insufflated ROA. Driving advisory verbatim from work-notes. Evidence basis: community_consensus_small
Afterglowtrace	7200–43200 sec(i=0.10)	7200–43200 sec(i=0.10)	low
Editorial	All timeline data from community consensus (PsychonautWiki, Grokipedia, Bluelight). No controlled pharmacokinetic studies. Work-notes specify onset 5-15 min, come_up 15-30 min, peak 1-3 hours, offset 1-2 hours, afterglow 2-12 hours for insufflated ROA. Driving advisory verbatim from work-notes.
	ReasoningReasoning All timeline data from community consensus (PsychonautWiki, Grokipedia, Bluelight). No controlled pharmacokinetic studies. Work-notes specify onset 5-15 min, come_up 15-30 min, peak 1-3 hours, offset 1-2 hours, afterglow 2-12 hours for insufflated ROA. Driving advisory verbatim from work-notes. Evidence basis: community_consensus_small

oral

Field	Published	AI Proposed	Confidence
Onsettrace	900–1800 sec(i=0.10)	900–1800 sec(i=0.10)	low
Editorial	Oral timeline data from limited community reports (Bluelight, Grokipedia). Work-notes specify onset 15-30 min, come_up 30-60 min, peak 1.5-3.5 hours, offset 1-3 hours, afterglow 2-12 hours. Fewer oral reports than insufflated; confidence is low. Driving advisory from work-notes (8 hours for oral route).
	ReasoningReasoning Oral timeline data from limited community reports (Bluelight, Grokipedia). Work-notes specify onset 15-30 min, come_up 30-60 min, peak 1.5-3.5 hours, offset 1-3 hours, afterglow 2-12 hours. Fewer oral reports than insufflated; confidence is low. Driving advisory from work-notes (8 hours for oral route). Evidence basis: community_consensus_small
Come uptrace	1800–3600 sec(i=0.35)	1800–3600 sec(i=0.35)	low
Editorial	Oral timeline data from limited community reports (Bluelight, Grokipedia). Work-notes specify onset 15-30 min, come_up 30-60 min, peak 1.5-3.5 hours, offset 1-3 hours, afterglow 2-12 hours. Fewer oral reports than insufflated; confidence is low. Driving advisory from work-notes (8 hours for oral route).
	ReasoningReasoning Oral timeline data from limited community reports (Bluelight, Grokipedia). Work-notes specify onset 15-30 min, come_up 30-60 min, peak 1.5-3.5 hours, offset 1-3 hours, afterglow 2-12 hours. Fewer oral reports than insufflated; confidence is low. Driving advisory from work-notes (8 hours for oral route). Evidence basis: community_consensus_small
Peaktrace	5400–12600 sec(i=1.00)	5400–12600 sec(i=1.00)	low
Editorial	Oral timeline data from limited community reports (Bluelight, Grokipedia). Work-notes specify onset 15-30 min, come_up 30-60 min, peak 1.5-3.5 hours, offset 1-3 hours, afterglow 2-12 hours. Fewer oral reports than insufflated; confidence is low. Driving advisory from work-notes (8 hours for oral route).
	ReasoningReasoning Oral timeline data from limited community reports (Bluelight, Grokipedia). Work-notes specify onset 15-30 min, come_up 30-60 min, peak 1.5-3.5 hours, offset 1-3 hours, afterglow 2-12 hours. Fewer oral reports than insufflated; confidence is low. Driving advisory from work-notes (8 hours for oral route). Evidence basis: community_consensus_small
Resolutiontrace	3600–10800 sec(i=0.35)	3600–10800 sec(i=0.35)	low
Editorial	Oral timeline data from limited community reports (Bluelight, Grokipedia). Work-notes specify onset 15-30 min, come_up 30-60 min, peak 1.5-3.5 hours, offset 1-3 hours, afterglow 2-12 hours. Fewer oral reports than insufflated; confidence is low. Driving advisory from work-notes (8 hours for oral route).
	ReasoningReasoning Oral timeline data from limited community reports (Bluelight, Grokipedia). Work-notes specify onset 15-30 min, come_up 30-60 min, peak 1.5-3.5 hours, offset 1-3 hours, afterglow 2-12 hours. Fewer oral reports than insufflated; confidence is low. Driving advisory from work-notes (8 hours for oral route). Evidence basis: community_consensus_small
Afterglowtrace	7200–43200 sec(i=0.10)	7200–43200 sec(i=0.10)	low
Editorial	Oral timeline data from limited community reports (Bluelight, Grokipedia). Work-notes specify onset 15-30 min, come_up 30-60 min, peak 1.5-3.5 hours, offset 1-3 hours, afterglow 2-12 hours. Fewer oral reports than insufflated; confidence is low. Driving advisory from work-notes (8 hours for oral route).
	ReasoningReasoning Oral timeline data from limited community reports (Bluelight, Grokipedia). Work-notes specify onset 15-30 min, come_up 30-60 min, peak 1.5-3.5 hours, offset 1-3 hours, afterglow 2-12 hours. Fewer oral reports than insufflated; confidence is low. Driving advisory from work-notes (8 hours for oral route). Evidence basis: community_consensus_small

Dose Tier Summaries

thresholdtrace

low

A barely perceptible alteration of consciousness. Spatial awareness shifts subtly — rooms may feel slightly larger or edges softer — accompanied by a faint mood lift and mild bodily lightness. Most users describe this level as sub-functional: present but not commanding attention. Physically, effects are minimal. A slight warmth or tingling may be noticed, and mild stimulation can occur, but motor control and coordination remain intact. Nausea is rare at this level. Functional impairment is negligible. The experience is brief and unlikely to interfere with routine activities, though driving or precision tasks should still be avoided until effects fully resolve.

Editorial

Work-notes threshold tier description expanded with substance-specific texture from community reports (Bluelight, PsychonautWiki). No controlled data; community consensus only.

Reasoning

Work-notes threshold tier description expanded with substance-specific texture from community reports (Bluelight, PsychonautWiki). No controlled data; community consensus only.

Evidence basis: community_consensus_small

lighttrace

low

Mild euphoria emerges with a distinctly stimulating quality that differentiates DMXE from ketamine at this dose level. Sociability is enhanced — conversation flows more easily, and social settings feel comfortable. Colors may appear slightly more vivid, and music takes on a warmer, more engaging texture. Bodily dissociation is subtle: a pleasant numbness or lightness without significant motor impairment. A gentle body high and warmth are characteristic. Touch sensitivity begins to decrease. Nausea is uncommon but possible, particularly via the oral route. Cognitive function is mostly preserved. The experience is manageable in social contexts, though judgment may be subtly affected. Compulsive redosing urge can emerge even at this level during the comedown — pre-measured dosing is advisable.

Editorial

Work-notes light tier expanded. Community reports consistently describe DMXE as more stimulating and sociable than ketamine at low doses (Bluelight Big & Dandy thread). No controlled studies.

Reasoning

Work-notes light tier expanded. Community reports consistently describe DMXE as more stimulating and sociable than ketamine at low doses (Bluelight Big & Dandy thread). No controlled studies.

Evidence basis: community_consensus_small

commontrace

low

Clear dissociative effects emerge. Motor control impairment becomes noticeable — walking is unsteady and fine motor tasks become difficult. Bodily dissociation deepens: numbness spreads, and the boundary between body and environment begins to blur. Euphoria intensifies with a warm, rounded quality frequently compared to MXE. Introspection enhancement is a defining feature at this tier. Thought patterns turn inward, and contemplative states arise naturally. Mild geometric visual distortions appear with eyes closed — patterning in cool-toned palettes. Music enhancement is prominent, and time alteration becomes apparent. Auditory distortion may add a reverberant quality to sounds. This is the tier where compulsive redosing urge is most consequential — the desire to extend or deepen the experience during the offset phase is commonly reported. Pre-portioning doses and removing access to remaining material is strongly recommended.

Editorial

Work-notes common tier expanded with effects taxonomy names and substance-specific detail from community reports. Compulsive redosing warning from Bluelight thread data.

Reasoning

Work-notes common tier expanded with effects taxonomy names and substance-specific detail from community reports. Compulsive redosing warning from Bluelight thread data.

Evidence basis: community_consensus_small

strongtrace

low

Pronounced dissociation from body and environment. Bodily dissociation is deep — the physical body may feel distant or absent. Motor control impairment is significant: standing and walking are unreliable, and users should remain seated or lying down. Touch suppression is marked, and pain suppression is prominent. Vivid closed-eye geometry emerges in characteristic turquoise, pink, and violet palettes. Internal hallucinations become elaborate — architectural and abstract spaces may be explored. Introspection deepens substantially, and depersonalization and derealization intensify. Amnesia begins to affect the experience, and memory fragmentation may prevent coherent recall of portions of the session. This tier approaches dissociative hole territory. Cognitive impairment and decision impairment are substantial. A sober sitter is essential. The duration commitment is significant — expect 4–6 hours of noticeable effects via insufflation, longer orally.

Editorial

Work-notes strong tier expanded. Geometric visual descriptions from Bluelight reports (turquoise/pink/violet palette). Amnesia and hole-approach warnings from community consensus.

Reasoning

Work-notes strong tier expanded. Geometric visual descriptions from Bluelight reports (turquoise/pink/violet palette). Amnesia and hole-approach warnings from community consensus.

Evidence basis: community_consensus_small

heavytrace

low

Complete environmental disconnection — the dissociative hole. Ego dissolution occurs: the sense of self fragments or dissolves entirely. Profound geometric and architectural internal hallucinations dominate the experience, with elaborate spatial environments constructed by the dissociated mind. External sensory input is largely or entirely absent. Total loss of motor control renders the user immobile. Amnesia is likely — large portions or the entirety of the experience may be unrecoverable. Delirium is possible, and confusion may persist well into the offset phase. Nystagmus is pronounced. Nausea and vomiting risk increases, creating aspiration hazard in the absence of a sitter. This tier carries the highest acute risk. A sober sitter is mandatory, and the user should be positioned on their side to protect the airway. Compulsive redosing at this level is dangerous — all remaining material should be secured before dosing. The margin between this tier and medical emergency is unknown due to the absence of LD₅₀ data.

Editorial

Work-notes heavy tier expanded with safety-critical warnings. Aspiration risk, sitter requirement, and unknown safety margin from research output. Delirium and amnesia from Bluelight/Erowid reports at 60+ mg insufflated.

Reasoning

Evidence basis: community_consensus_small

History

current version

published Oct 2, 2026system—

versions

2 total · since previous: +3 / −3 citations

+ Deoxymethoxetamine (DMXE) New Drug Monograph — NPS Discovery (2025)

+ Deoxymethoxetamine — Chemical and pharmacological data compilation (Grokipedia) (2024)

+ Schedules of Controlled Substances: Placement of Methoxetamine (MXE) in Schedule I (2022)

− Deoxymethoxetamine - NPS Discovery Monograph (2025)

− Deoxymethoxetamine - Grokipedia (2024)

− Schedules of Controlled Substances: Placement of Methoxetamine (MXE) in Schedule I (2022)

publication ledger

publish Oct 2, 2026 · by agent-psx

backfill Jun 4, 2026

Historical versions do not record which reviewer approved them; editorial accountability is recorded per value in the database and in the publication ledger going forward.

full version history suggest a correction contact@psychedex.org

Sources

2 strong · 10 moderate · 13 weak

[1]
moderate
Derivatives of methoxetamine and major methoxetamine metabolites potently block NMDA receptors
Irie T, Yanase Y, Demizu Y, Usami M, Kikura-Hanajiri R · 2022 · Journal of Pharmacological Sciences
doi.org/10.1016/j.jphs.2022.09.005 pubmed 36344045no claims checked
[2]
moderate
1,2-Diarylethylamine- and Ketamine-Based New Psychoactive Substances
Wallach J, Brandt SD · 2018 · Handbook of Experimental Pharmacology
doi.org/10.1007/164_2018_148 pubmed 30196446no claims checked
[3]
moderate
Identification of Three Arylcyclohexylamines (MXPr, MXiPr, and DMXE) in Illegal Products
Tanaka R, Kawamura M, Mizutani S, Hakamatsuka T, Kikura-Hanajiri R · 2022 · Yakugaku Zasshi (Journal of the Pharmaceutical Society of Japan)
doi.org/10.1248/yakushi.21-00235 pubmed 35650087no claims checked
[4]
moderate
Chiral Separation and Determination of Enantiomer Elution Order of Novel Ketamine Derivatives Using CE-UV and HPLC-UV-ORD
Seibert E, Hubner EM, Schmid MG · 2025 · Separations
doi.org/10.3390/separations12020044no claims checked
[5]
weak
Analytical findings of an acute intoxication after inhalation of methoxetamine
Imbert L, Boucher A, Delhome G, Cueto T, Boudinaud M, Maublanc J, Dulaurent S, Descotes J, Lachatre G, Gaulier JM · 2014 · Journal of Analytical Toxicology
doi.org/10.1093/jat/bku052 pubmed 24904014no claims checked
[6]
weak
Dorsolateral Prefrontal Cortex Impairment in Methoxetamine-Induced Psychosis: An 18F-FDG PET/CT Case Study
Moccia L, Tofani A, Mazza M, Covino M, Martinotti G, Schifano F, Janiri L, Di Nicola M · 2019 · Journal of Psychoactive Drugs
doi.org/10.1080/02791072.2019.1578444 pubmed 30741111no claims checked
[7]
strong
What urologists need to know about ketamine-induced uropathy: A systematic review
Castellani D, Pirola GM, Gubbiotti M, Rubilotta E, Gudaru K, Gregori A, Dellabella M · 2020 · Neurourology and Urodynamics
doi.org/10.1002/nau.24341 pubmed 32212278no claims checked
[8]
weak
Deoxymethoxetamine - Wikipedia
2024
linkno claims checked
[9]
weak
Deoxymethoxetamine (DMXE) New Drug Monograph — NPS Discovery
Center for Forensic Science Research and Education (CFSRE) · 2025
linkno claims checked
[10]
weak
Deoxymethoxetamine - NCATS Inxight Drugs (FDA UNII: G32GTT7MGW)
2024
linkno claims checked
[11]
moderate
The ketamine analogue methoxetamine and 3- and 4-methoxy analogues of phencyclidine are high affinity and selective ligands for the glutamate NMDA receptor
Roth BL, Gibbons S, Arunotayanun W, Huang XP, Setola V, Treble R, Iversen L · 2013 · PLoS ONE
doi.org/10.1371/journal.pone.0059334 pubmed 23527166no claims checked
[12]
moderate
Ketamine-derived designer drug methoxetamine: metabolism including isoenzyme kinetics and toxicological detectability using GC-MS and LC-(HR-)MSn
Meyer MR, Bach M, Welter J, Bovens M, Turcant A, Maurer HH · 2013 · Analytical and Bioanalytical Chemistry
doi.org/10.1007/s00216-013-7051-6 pubmed 23774830no claims checked
[13]
moderate
Ketamine for Depression: Advances in Clinical Treatment, Rapid Antidepressant Mechanisms of Action, and a Contrast with Serotonergic Psychedelics
Kojic M, Saelens J, Kadriu B, Zarate CA, Kraus C · 2022 · Current Topics in Behavioral Neurosciences
doi.org/10.1007/7854_2022_313 pubmed 35312993no claims checked
[14]
moderate
The novel methoxetamine analogs N-ethylnorketamine, 2-MeO-N-ethylketamine, and 4-MeO-N-ethylketamine elicit rapid antidepressant effects via activation of AMPA and 5-HT2 receptors
Sayson LV, Botanas CJ, Custodio RJP, Abiero A, Kim M, Lee HJ, Kim HJ, Yoo SY, Lee KW, Ryu HW, Acharya S, Kim KM, Lee YS, Cheong JH · 2019 · Psychopharmacology
doi.org/10.1007/s00213-019-05219-x pubmed 30891619no claims checked
[15]
moderate
Methoxetamine, a novel psychoactive substance with serious adverse pharmacological effects: a review of case reports and preclinical findings
Zanda MT, Fadda P, Chiamulera C, Fratta W, Fattore L · 2016 · Behavioural Pharmacology
doi.org/10.1097/fbp.0000000000000241 pubmed 27128862no claims checked
[16]
weak
Deoxymethoxetamine (DMXE) - PsychonautWiki Talk Page
2024
linkno claims checked
[17]
weak
Deoxymethoxetamine — Chemical and pharmacological data compilation (Grokipedia)
Grokipedia contributors · 2024
linkno claims checked
[18]
strong
Designer drugs: mechanism of action and adverse effects
Luethi D, Liechti ME · 2020 · Archives of Toxicology
doi.org/10.1007/s00204-020-02693-7 pubmed 32249347no claims checked
[19]
weak
Rhabdomyolysis and Acute Kidney Injury after Use of 3-Methyl-PCP: A Case Report
Deutsch AB, Ebeling-Koning NE, Krotulski AJ, Walton SE, Katz KD · 2026 · Journal of Medical Toxicology
doi.org/10.1007/s13181-026-01122-y pubmed 41770514no claims checked
[20]
weak
A Fatal Case Involving N-Ethyldeschloroketamine (2-Oxo-PCE) and Venlafaxine
Theofel N, Möller P, Vejmelka E, Kastner K, Roscher S, Scholtis S, Tsokos M · 2019 · Journal of Analytical Toxicology
doi.org/10.1093/jat/bky063 pubmed 30365028no claims checked
[21]
moderate
British Association of Urological Surgeons Consensus statements on the management of ketamine uropathy
Belal M, Downey A, Doherty R, Ali A, Hashim H, Kozan A, Kujawa M, Pakzad M, Rashid T, Osman N, Sahai A, Biers S · 2024 · BJU International
doi.org/10.1111/bju.16404 pubmed 38778743no claims checked
[22]
weak
3-Methoxy-Phencyclidine Induced Psychotic Disorder: A Literature Review and an 18F-FDG PET/CT Case Report
Pepe M, Di Nicola M, Cocciolillo F, Chiappini S, Martinotti G, Calcagni ML, Sani G · 2024 · Pharmaceuticals (Basel)
doi.org/10.3390/ph17040452 pubmed 38675413no claims checked
[23]
weak
DMXE Experience Reports Index
Erowid · 2024
linkno claims checked
[24]
weak
Schedules of Controlled Substances: Placement of Methoxetamine (MXE) in Schedule I
US Drug Enforcement Administration · 2022
linkno claims checked
[25]
weak
Beyond Ketamine and Phencyclidine: Analytically Confirmed Use of Multiple Novel Arylcyclohexylamines
Thornton S, Lisbon D, Lin T, Gerona R · 2017 · Journal of Psychoactive Drugs
doi.org/10.1080/02791072.2017.1333660 pubmed 28590798no claims checked

Claim Verification

No claim verification has run for this version.

Coverage & Gaps

effect links

194 links · 194 approved · 0 audited0/194 with evidence basis

DMXE

Value Provenance

Dosing

insufflatedtrace →

oraltrace →

Duration

insufflated

oral

Safety

Toxicity Profiletrace →

Dependence Profiletrace →

Withdrawal Profiletrace →

Tolerance Profiletrace →

Effects & Profile

Contraindications

Timeline Phases

insufflated

oral

Dose Tier Summaries

History

Sources

Claim Verification

Coverage & Gaps

insufflatedtrace

oraltrace

Toxicity Profiletrace

Dependence Profiletrace

Withdrawal Profiletrace

Tolerance Profiletrace